Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Zdenka E Segota"'
Autor:
Zdenka E Segota, Susie Sennhauser, Joy O Young-Ramsaran, Carolina G Valdes, Margaret J Gorensek, Edgar L Bustamante
Publikováno v:
Clinical Infectious Diseases. 70:2450-2453
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b0158c71f48a936223ffe8cbda5deb1
https://doi.org/10.1093/cid/ciz796
https://doi.org/10.1093/cid/ciz796
Autor:
Bita Nehoray, Arti Hurria, Kenneth Bruce Blankstein, Catherine A. Marcum, Zdenka E Segota, Sharon Sand, Kathleen R. Blazer, Thomas P. Slavin, Carolyn B. Hendricks, Sandra Brown, Jeffrey N. Weitzel, Yanin Chavarri-Guerra, Mary Hander, Enrique Soto-Perez-de-Celis, Chris Hake
Publikováno v:
J Am Geriatr Soc
BACKGROUND/OBJECTIVES Women diagnosed with breast cancer (BC) at an older age are less likely to undergo genetic cancer risk assessment and genetic testing since the guidelines and referrals are biased toward earlier age at diagnosis. Thus, we determ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e6b624aab3566a7728166ac22a7c983
https://doi.org/10.1111/jgs.15937
https://doi.org/10.1111/jgs.15937
Autor:
A. Ardeljan, Omar M. Rashid, G. Azzi, L. Siegel, Susie Sennhauser, A. Johns, D. Drew, D. Dammrich, D. Maurente, S. Willis, L. Ramsaran, M. Ghali, Zdenka E Segota, M. Bustos
Publikováno v:
HPB. 20:S166-S167
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00729c69df9409e5febb5e4f34c5fc3b
https://doi.org/10.1016/j.hpb.2018.02.619
https://doi.org/10.1016/j.hpb.2018.02.619
Autor:
Enrique Soto Perez De Celis, Kenneth Bruce Blankstein, Ilana Solomon, Christina Rybak, Mary Hander, Carolyn B. Hendricks, Kathleen R. Blazer, Bita Nehoray, Zdenka E Segota, Howard Ho Wing Cheng, Kisa Weeman, Suhasini Nadesan, Lily Kuzmich, Sandra Brown, Arti Hurria, Lily R. Van Tongeren, Sharon Sand, Jeffrey N. Weitzel, Yanin Chavarri Guerra
Publikováno v:
Journal of Clinical Oncology. 35:e13030-e13030
e13030 Background: Older women with BC are less likely to undergo genetic cancer risk assessment since a hallmark of hereditary BC is younger age at onset. Hence there are limited data regarding genetic risk assessment findings in older women with BC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ce0be7f35d2b0fa2a35db4a7f3ab580
https://doi.org/10.1200/jco.2017.35.15_suppl.e13030
https://doi.org/10.1200/jco.2017.35.15_suppl.e13030
Autor:
Adam D. Cohen, John M. Timmerman, Ivan Borrello, Jon M. Wigginton, Moshe Talpaz, Su Young Kim, Martin Gutierrez, Stephen M. Ansell, Deepika Cattry, Ashok Kumar Gupta, Christina Hartman, Maria Mezes, Ahmad Halwani, Alexander M. Lesokhin, Tracy Turner, Zdenka E Segota, Philippe Armand
Publikováno v:
Journal of Clinical Oncology. 31:TPS3113-TPS3113
TPS3113 Background: Programmed death-1 (PD-1) is an immune checkpoint receptor that inhibits T-cell activation upon interaction with its ligands PD-L1 or PD-L2. Increased PD-L1 expression has been reported with various hematologic malignancies and ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9eb85b20159ea556de8c43a5629f05ae
https://doi.org/10.1200/jco.2013.31.15_suppl.tps3113
https://doi.org/10.1200/jco.2013.31.15_suppl.tps3113
Autor:
David Weng, Ravi K. Amaravadi, Zdenka E Segota, Kyriakos P. Papadopoulos, Lainie P. Martin, Alex A. Adjei, Neil Senzer, Martin C. Graham, Russell J. Schilder, Patricia LoRusso
Publikováno v:
Journal of Clinical Oncology. 31:3621-3621
3621 Background: Birinapant (B) is a SMAC-mimetic that inhibits IAPs and has potent preclinical anti-tumor synergy combined with TNFa-inducing chemotherapies [i.e irinotecan (I)]. B and I combination is well-tolerated and has encouraging activity in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::471f2dcf4f9a1c6a4a0703013c35866d
https://doi.org/10.1200/jco.2013.31.15_suppl.3621
https://doi.org/10.1200/jco.2013.31.15_suppl.3621